Epitomics, Inc. a biotechnology company commercializing the next generation of antibodies based on its groundbreaking Rabbit Monoclonal (RabMAb) technology, announced the company has now launched 23 novel cancer related antibodies that were developed through a partnership with the National Cancer Institute’s Centre for Cancer Research. The goal of this partnership is to develop novel, high quality reagents for cancer research and make them available to the scientific community.
“We are very excited to see the progress we have made in developing several key antibodies with NCI investigators and look forward to continuing working with them to develop high quality rabbit monoclonal antibodies.” said Dr Guo-Liang Yu, CEO, Epitomics, Inc.
All of the antibodies made under the collaboration are available for purchase in the USA directly through Epitomics and around the world through Epitomics international distributors. It is anticipated that another 20 antibodies will be developed through this partnership and released by Epitomics over the next 2 years.
Epitomics, Inc, is a biotechnology company dedicated to developing breakthrough monoclonal antibody technology for research and diagnostic applications.